Viewing Study NCT00220194

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 1:40 AM

Ignite Modification Date: 2025-12-26 @ 4:02 AM

Study NCT ID: NCT00220194

Status: COMPLETED

Last Update Posted: 2016-10-14

First Post: 2005-09-17

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

Sponsor: San Bernardino Urological Associates Medical Group Inc

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module